PT Pyridam Farma Tbk (IDX: PYFA) is executing its Capital Increase with Pre-emptive Rights II (PMHMETD II), commonly known as a rights issue, after securing shareholder approval during the Extraordinary General Meeting of Shareholders (EGMS) held in April 2026. This approval marks a significant milestone in the Company’s transformation journey to build an integrated healthcare ecosystem, aligning with its efforts to enhance competitiveness and create long-term value for shareholders.

Citing the abridged prospectus, the Company plans to issue a maximum of 5.7 billion new shares with a nominal value of Rp100 per share, accompanied by the issuance of warrants in accordance with applicable regulations. The proceeds obtained will be used prudently by the Company to strengthen its capital structure and fund potential acquisitions to support its business development. This measure is part of a broader strategy to accelerate expansion and solidify its position within the integrated healthcare industry ecosystem.

“The Company would like to express its gratitude for the shareholders’ trust. With the approval we have obtained, we will certainly focus on completing our ecosystem. The Company believes that as a pharmaceutical enterprise, providing the best healthcare products and services equipped with cutting-edge technology to the public is our fundamental obligation and responsibility,” stated Sinta L. Ningsih, Director of PYFA.

In addition to the issuance of new shares, the Company is also incorporating warrants as part of the corporate action structure. The maximum number of warrants offered is 35% of the total issued and fully paid-up shares at the time the registration statement is submitted to the Financial Services Authority (OJK). The issuance of these warrants is expected to provide added value for shareholders who exercise their rights, while simultaneously unlocking potential additional capital for the Company in the future through warrant conversions.

The Company targets the rights issue process to proceed in stages, starting from the shareholder approval in April 2026 to obtaining the effective statement from the OJK by the end of June 2026. Subsequently, the pre-emptive rights exercise period is scheduled to take place in July 2026, with the entire series of corporate actions targeted for completion in the third quarter of 2026.

Moving forward, the Company will continue to prioritize an adaptive and measured growth strategy. This will focus on optimizing its business portfolio through acquisitions, strengthening operational fundamentals, and creating long-term value for all stakeholders, in strict adherence to the principles of good corporate governance.

About PYFA

PT Pyridam Farma Tbk, also known as PYFA, is a public pharmaceutical company listed on the Indonesia Stock Exchange (Ticker: PYFA). PYFA operates several business units producing prescription medicines in various forms, including tablets, capsules, creams, and injections. PYFA also has several well-known subsidiaries, including PT Holi Pharma, PT Ethica Industri Farmasi, and Probiotec Multipack.

Media Relations

Leilanie Nadia Kusuma
Head of Corporate Communications
Website : www.pyfa.co.id
Email : corcomm@pyfa.co.id